FUJIFILM Pharmaceuticals U.S.A., Inc.

Clinical trials sponsored by FUJIFILM Pharmaceuticals U.S.A., Inc., explained in plain language.

Now part of FUJIFILM Holdings Corporation FUJIY OTC

A subsidiary of FUJIFILM, developing and marketing pharmaceuticals.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

Can a new gemcitabine formulation outsmart advanced solid tumors? Results expected Oct 2026 (estimated)
New liposome chemo shows promise in early cancer trial Results expected Dec 2026 (estimated)

Browse trials soon ready across all sponsors →

Not yet finished but already full! 3 Completed 1

New cancer drug shows promise in early trial for Tough-to-Treat tumors

Disease control Completed

This study tested a new drug called FF-10502-01 in 106 adults with advanced solid tumors or lymphomas that had stopped responding to standard treatments. The goal was to find the safest dose and see if the drug could shrink tumors or slow disease progression. While not a cure, th…

Phase 1/2 • Sponsor: Fujifilm Pharmaceuticals U.S.A., Inc. • Aim: Disease control

Last updated Jun 27, 2026 12:23 UTC

FUJIFILM Pharmaceuticals U.S.A., Inc.

Upcoming readouts

New cancer drug shows promise in early trial for Tough-to-Treat tumors